NAD+ vs NMN: Differences, Evidence & UK Status

The direct answer: NAD+ and NMN are not the same thing. NAD+ (nicotinamide adenine dinucleotide) is the coenzyme cells use in energy metabolism and other cellular processes. NMN (nicotinamide mononucleotide) is a precursor that the body can use within pathways that produce NAD+.

For UK shoppers, there is another important difference: the human evidence and the regulatory position are not identical. NMN has a growing human trial base showing changes in blood NAD-related markers, but broader health outcomes remain inconsistent. In Great Britain, β-NMN application RP-2116 is still listed by the Food Standards Agency as “In progress” at risk assessment as of 18 October 2026. An application in progress is not the same as an authorisation.

This guide compares direct NAD+ vs NMN by biology, evidence, formulation and current GB status without declaring a simplistic winner.

NAD+ vs NMN at a glance

What is NAD+?

NAD+ stands for nicotinamide adenine dinucleotide. It is an essential coenzyme found throughout the body. It helps transfer electrons in reactions involved in converting nutrients into usable cellular energy and is also consumed by enzymes including sirtuins, PARPs and CD38.

That biology is important, but it should not be converted into an automatic supplement claim. A molecule can be essential to normal physiology without an oral supplement being proven to improve energy, reverse ageing, extend lifespan or produce a specific customer outcome.

For the wider science, read What Does an NAD+ Supplement Do? Evidence and Forms.

What is NMN?

NMN, or nicotinamide mononucleotide, is a compound within the network of pathways the body can use to make NAD+. It is therefore usually described as an NAD+ precursor.

The practical distinction is simple: taking NMN means taking a precursor that must be processed through metabolism; taking a direct-NAD product means the label provides NAD+ itself. That does not prove that direct oral NAD+ reaches cells more efficiently, bypasses every metabolic step or produces a stronger result.

What does the 2026 human evidence say about NMN?

The most consistent human finding for NMN is biochemical target engagement: some studies show increases in blood NAD+ or related metabolites.

A 2026 randomised, open-label, placebo-controlled study in 65 healthy adults compared nicotinamide, nicotinamide riboside (NR), NMN and placebo over 14 days. NR and NMN produced comparable chronic increases in baseline whole-blood NAD+ concentrations. That is useful evidence that both precursors can affect the NAD system in humans.

However, a higher blood NAD+ measurement is not the same as proving improved energy, cognition, physical performance or longevity.

A separate 2026 randomised, double-blind, placebo-controlled trial in adults aged 65 and over tested 1,250mg NMN daily for 24 weeks. Blood NAD+ and related metabolites increased, but the study did not find significant improvement in its primary auditory outcome or physical-performance measures. Exploratory changes in some other measures did not remain significant after correction for multiple testing.

This is an important evidence boundary: NMN can influence NAD-related biomarkers, while evidence for broader functional benefit remains much less settled.

What about direct oral NAD+?

Direct oral NAD+ has a thinner human randomised-trial evidence base than NR or NMN. This means evidence from precursor trials should not be transferred automatically to a direct-NAD supplement.

There is also no robust human oral head-to-head trial establishing that a direct NAD+ capsule is clinically superior to NMN. Statements such as “direct NAD+ is better because it skips conversion” go beyond what current human evidence can establish.

A transparent direct-NAD product can still have a clear role for shoppers who specifically want the coenzyme itself rather than a precursor. The evidence should simply remain form-specific.

Does NAD+ always decline with age?

This common category claim also needs nuance. A major 2026 multi-cohort human study found that whole-blood NAD+ levels remained remarkably stable with age across seven independent cohorts, challenging the idea that blood NAD+ is a universal ageing biomarker.

That does not prove NAD biology is unchanged in every tissue. Muscle, liver, brain and blood are different biological compartments. It does show why strong claims such as “NAD+ inevitably collapses as you age” are too broad.

NAD+ vs NMN: which has stronger human evidence?

If the question is specifically which form has more human oral research showing a rise in blood NAD-related markers, NMN currently has more direct evidence than oral direct NAD+.

If the question is which has been proven to improve healthy ageing outcomes, the answer is much less satisfying: neither has established a universal clinical benefit that justifies anti-ageing, life-extension or guaranteed-energy claims.

A useful way to think about the evidence is:

• NAD biology: well established.
• NMN biomarker effects: supported by several human studies.
• Direct oral NAD+ biomarker/outcome evidence: comparatively limited.
• Meaningful longevity or broad functional outcomes: not established for either as a general consumer claim.

What is the current UK status of NMN?

This is where a comparison for UK shoppers becomes materially different from a generic global article.

As of 18 October 2026, the Food Standards Agency register shows application RP-2116 for β-Nicotinamide Mononucleotide as:

• Status: In progress
• Phase: Risk assessment
• Product type: Novel foods

Great Britain novel foods must be authorised before they can be placed on the market. The FSA’s GB authorised novel-food register currently includes nicotinamide riboside chloride as an authorised novel food, while the β-NMN application above is still progressing through assessment.

An application being assessed does not mean the ingredient has been authorised. Consumers and businesses should therefore distinguish between an ingredient appearing in an application register and an ingredient appearing on the authorised register.

This GB discussion applies to England, Scotland and Wales. Northern Ireland follows a separate route for novel-food authorisation under the applicable EU framework.

Does that make NMN “bad” or ineffective?

No. Regulatory authorisation and scientific efficacy are different questions.

A regulatory process assesses whether a novel food can be authorised for market use under specified conditions. A clinical study asks whether an intervention changes a measured biological or health outcome. One cannot substitute for the other.

The correct interpretation is that NMN has human research interest and measurable biochemical effects in some trials, while its current GB market-authorisation position must be treated separately and accurately.

Where Ayaani’s direct NAD+ formula fits

Ayaani Liposomal NAD+ with Resveratrol is not an NMN product. Its current two-capsule serving provides:

• 1,200mg direct NAD+;
• 300mg trans-resveratrol from 98% Polygonum cuspidatum root extract;
• a non-GMO sunflower-phospholipid liposomal matrix;
• two plant-based capsules once daily; and
• 80 capsules, providing 40 daily servings.

The most accurate positioning is therefore straightforward: Ayaani offers a direct-NAD+ formulation for customers who prefer NAD+ itself rather than NMN or NR.

It should not borrow NMN trial results as proof of what the Ayaani finished product will do. It should also not imply that direct NAD+ has already been proven clinically superior to NMN.

For the exact formula and serving guide, read Liposomal NAD+ 1200mg with Resveratrol: Formula Guide.

What about liposomal delivery?

Liposomal describes a lipid-based formulation approach. It can be a genuine product-design feature, but the word alone does not establish superior human absorption or clinical outcomes.

Ayaani identifies a sunflower-phospholipid matrix in its formula. That is useful formulation transparency. It is not the same thing as having a finished-product human trial proving that the formula delivers more NAD+ to blood or tissues than NMN, NR or a standard capsule.

NAD+ vs NMN: which should a shopper choose?

There is no evidence-based universal winner.

A shopper who specifically wants the form with more human data on increasing blood NAD-related markers may be drawn to NMN or NR research. In Great Britain, however, regulatory status is part of the purchasing decision and should be checked before treating a product as a straightforward authorised supplement option.

A shopper who specifically wants direct NAD+ may prefer a clearly labelled direct-NAD formulation, while accepting that oral human evidence for direct NAD+ is currently thinner.

The better buying process is to compare:

1. Exact ingredient form — direct NAD+, NMN or NR.
2. Human evidence for that same form.
3. Biomarker results versus meaningful health outcomes.
4. Current UK/GB regulatory status.
5. Daily serving and supporting ingredients.
6. Formulation claims such as liposomal delivery.
7. Medication, medical and dietary suitability.

For a broader purchasing framework, see Best NAD+ Supplements UK: 7 Checks Before You Buy.

Common claims to treat cautiously

• “NMN reverses ageing.” Human evidence does not justify that claim.
• “Direct NAD+ is automatically better because there is no conversion step.” That is a mechanistic simplification, not a proven clinical advantage.
• “Higher blood NAD+ means you will feel more energetic.” Biomarkers and felt outcomes are not interchangeable.
• “Liposomal means 100% absorption.” Delivery terminology does not prove a universal percentage.
• “An FSA application means the ingredient is approved.” An in-progress application is not an authorisation.

Frequently asked questions

Is NAD+ the same as NMN?

No. NAD+ is the coenzyme itself. NMN is a precursor that can contribute to NAD+ synthesis.

Does NMN increase NAD+ in humans?

Several human studies report increases in blood NAD+ or related metabolites after NMN supplementation. That does not establish universal improvements in energy, performance, cognition or longevity.

Is direct NAD+ proven better than NMN?

No. Direct oral NAD+ has a smaller human evidence base, and there is no robust evidence establishing universal clinical superiority over NMN.

Is NMN authorised in Great Britain?

As of 18 October 2026, FSA application RP-2116 for β-NMN is still listed as in progress at risk assessment. Great Britain novel foods require authorisation before being placed on the market, so an in-progress application should not be described as an authorisation.

Is nicotinamide riboside the same as NMN?

No. NR and NMN are different NAD+ precursors. Nicotinamide riboside chloride appears on the GB authorised novel-food register under specified conditions of use.

Does Ayaani contain NMN?

No. Ayaani’s current product provides 1,200mg direct NAD+ and 300mg trans-resveratrol per two-capsule daily serving.

The bottom line

NAD+ vs NMN is not a simple contest between “direct” and “precursor”. NMN currently has stronger human evidence for raising selected blood NAD-related biomarkers, but broader functional outcomes remain uncertain and its GB novel-food application is still in progress. Direct oral NAD+ offers a different ingredient proposition, but its human oral evidence base is thinner.

For Ayaani, the correct position is clear: 1,200mg direct NAD+ with 300mg trans-resveratrol, transparently separated from NMN evidence and from claims the science does not yet justify.

References and further reading

1. Food Standards Agency: β-Nicotinamide Mononucleotide application RP-2116
2. GOV.UK: Novel foods authorisation guidance
3. Food Standards Agency: Nicotinamide riboside chloride authorisation
4. Christen S et al. Human comparison of NAD+ precursors, Nature Metabolism (2026)
5. 24-week randomised NMN trial in older adults, npj Aging (2026)
6. Human whole-blood NAD+ across age and lifestyle interventions, Nature Metabolism (2026)
7. Systematic review of NAD-related supplementation evidence (2026)

About the author
Ayaani Wellness Team creates practical, evidence-aware guidance to help readers make more informed supplement and daily-routine choices.

Food supplements should not replace a varied, balanced diet and healthy lifestyle. Follow the product label and do not exceed the recommended daily amount. Speak with a pharmacist, GP or qualified healthcare professional before using a new supplement if you are pregnant, breastfeeding, taking medication, have a medical condition or are unsure whether it is suitable for you. Regulatory information can change; this article reflects the cited Great Britain position checked on 18 October 2026.